RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical trial design for RGN-137 to treat epidermolysis bullosa (“EB”). RGN-137 is a dermal wound healing gel that incorporates Thymosin beta 4 (“Tβ4”) as the active pharmaceutical ingredient. GtreeBNT is planning to enter into the Phase 3 trial in the U.S. during the third quarter of 2017.
{iframe}http://www.regenerx.com/2017-02-27-RegeneRx-Licensee-Receives-FDA-Permission-to-Conduct-a-Phase-3-Trial-of-RGN-137-for-Epidermolysis-Bullosa-in-U-S?utm_source=MD+BioHealth+Spring+Update&utm_campaign=4%2F27&utm_medium=email{/iframe}